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A model of the pi cycle reveals 
the regulating roles of lipid‑binding 
proteins and pitfalls of using 
mosaic biological data
francoise Mazet1*, Marcus J. tindall2, Jonathan M. Gibbins1 & Michael J. fry1
the phosphatidylinositol (pi) cycle is central to eukaryotic cell signaling. its complexity, due to the 
number of reactions and lipid and inositol phosphate intermediates involved makes it difficult to 
analyze experimentally. computational modelling approaches are seen as a way forward to elucidate 
complex biological regulatory mechanisms when this cannot be achieved solely through experimental 
approaches. Whilst mathematical modelling is well established in informing biological systems, many 
models are often informed by data sourced from multiple unrelated cell types (mosaic data) or from 
purified enzyme data. In this work, we develop a model of the PI cycle informed by experimental 
and omics data taken from a single cell type, namely platelets. We were able to make a number of 
predictions regarding the regulation of pi cycle enzymes, the importance of the number of receptors 
required for successful GpcR signaling and the importance of lipid‑ and protein‑binding proteins in 
regulating second messenger outputs. We then consider how pathway behavior differs, when fully 
informed by data for HeLa cells and show that model predictions remain consistent. However, when 
informed by mosaic experimental data model predictions greatly vary illustrating the risks of using 
mosaic datasets from unrelated cell types.
The phosphatidylinositol (PI) cycle is a key component of the signaling machinery downstream of receptor 
protein-tyrosine kinases (RTK) and G protein-coupled receptors (GPCR). The cycle can be found in all eukaryotic 
cells, is the source of multiple second messengers through the actions of phospholipase C (PLC) and phospho-
inositide 3-kinase (PI3K) and is assumed to function the same way in different cell types. The universal nature 
of the pathway means it is of wide interest, but its multiple components are technically difficult to measure, 
making it a good candidate to explore using mathematical modelling approaches. There has been a number of 
prior attempts to model aspects of the PI cycle looking at portions of the signaling cascade using ordinary dif-
ferential equations (ODEs), informed to a large degree by data from different cell  types1–3. We have been unable, 
however, to combine them into a single model of the complete pathway and recapitulate the different published 
biological outputs. This issue applies to a number of cell signaling models, with their development being ham-
pered by a lack of cell type specific biological data to inform kinetic rate constants and protein concentrations. 
In particular, we note current cell signaling pathway models often lack cell-specific time course data to inform 
model parameter values. They also usually incorporate purified enzyme kinetic data which may bear little resem-
blance to the cellular  kinetics4, or experimental values obtained from multiple, unrelated, cell types, with reactant 
concentrations often estimated. Signaling can be cell context dependent producing specific responses to stimuli 
and “mosaic” models. Although useful in investigating and informing the general biological processes involved, 
models informed in these ways may not necessarily recapitulate cell specific dynamic behaviors.
We postulate that cell-type specific datasets generated by omics approaches coupled to time-course analysis 
of the gene expression or protein modifications would provide a more consistent approach to informing math-
ematical models. This would allow us to focus on determining in-situ reaction kinetic rate constants which 
once obtained should be possible to use for other cell types as long as specific quantitative proteomic data are 
available. Here we describe a PI cycle model making use of a quantitative proteomic  dataset5 and experimental 
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phospholipid (PL) and inositol phosphate (IP) time-course data produced in platelets, under similar conditions 
(Fig. 1A)6–11. We use the model to demonstrate the importance of lipid-binding proteins in regulating homeo-
stasis and to inform the regulation of several key proteins in platelets. We next investigate how the model can be 
used to simulate the PI cycle in other cell types. In doing so we leave our rates unchanged but inform the model 
with specific cell-type proteomic data (Fig. 1B). Finally, we demonstrate the pitfalls of using mosaic data to inform 
such a model and how it can lead to erroneous conclusions. We discuss how this limits the use of combining cell 
signaling models and directing the design of future experiments.
Results
We first sought to combine previously published mathematical models of the PI pathway in order to construct 
a model of the pathway in platelets. Whilst the structure of the pathways and their respective mathematical for-
mulations were generally similar, how the respective reaction rate constants and concentrations were informed 
varied greatly. For instance, values were not consistently reported both in terms of their magnitude and units, it 
was not always clear how all values had been informed and values to inform cell type specific models had been 
obtained from data related to different cell types. We also sought to consider a previous model of PI signalling 
in platelets in response to ADP  signalling1, which we could extend to model the response of platelets to a variety 
of GPCR ligands. We found that whilst the model had been useful in informing platelet biology, it was informed 
using a range of different cell type parameter data and experimental results from both ADP and Thrombin but 
only considering ADP receptor to trigger the cell activation.
In light of these points and knowing that considerable biological data for informing platelet biology is now 
available, we thus decided to formulate a complete model of the PI cycle in platelets, exclusively using specific 
parameters for PI cycle pathway proteins, phospholipid substrates and resulting second messengers (Fig. 2). In 
respect of platelet specific data, literature mining revealed three quantitative proteomes for human and mouse 
platelets and HeLa cells that contained data on all the key proteins required for the PI cycle to  function5,12,13. 
Further literature mining revealed that detailed sets of time-resolved data on complexes formed in the PI cycle 
pathway were also available for human platelets (Fig. 3A,C, Supplementary Figure S1 online). Using this infor-
mation, we first developed a human platelet “Core Model” that focuses on G protein-coupled receptor (GPCR) 
signaling through Gαq, leading to PLCβ activation and production of inositol 1,4,5-trisphosphate (IP3) second 
messenger. Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), produced via Gαi and PI3K, and other PIP3-
derived PL were also monitored, but their highest levels were systematically two orders of magnitude lower than 
PL and Inositol (Ins)9,14 (Fig. 2A, Supplementary Figure S1 and Supplementary Table S1 online). As such, we 
assumed they are unlikely to significantly alter the PLCβ results and conclusions and subsequently were excluded 
in the model we developed.
the core model—the human platelet model. We constructed an ODE model of the PI cycle in human 
platelets based on the model shown in Fig. 2A, which was solved in COPASI (v4)15. Full details on how the model 
was developed, parameterized and solved are presented in the Supplementary Information. Briefly, in order to 
accurately inform the full model parameterization and given the full model consisted of 35 parameter values, we 
decided to use an iterative approach of reduced models to both decrease the size of the parameter space being 
determined, whilst increasing confidence in the parameter values determined. We started with the most simpli-
fied model (iterations 1 and 2) shown in Fig. 2B, and via model-data fitting using the parameter estimation algo-
rithm available in  COPASI15, used this to inform the relevant parameter values. This model was then extended 
in the next iteration with a number of additional reactions, which were chosen so as to not greatly increase the 
size of the undetermined parameter set. Each model was informed where possible with the previously deter-
mined values, whilst new unknown parameter values were again determined. Iterative steps in building up the 
complexity of our model in this way, allowed us to inform the full model pathway as detailed in Supplementary 
Tables S1-S5, Supplementary Figure S2 and the Supplementary Information online.
phospholipid binding proteins stabilize phospholipids variations. An important point that arose 
during the development of the Core Model, was that solely adapting the rates of production or recycling of dif-
ferent PL to switch from non-actived to activated states, and back again did not lead to a biologically realistic 
solution (Supplementary Figure S3 online). We concluded that the problem was linked to the availability of PL to 
the enzymes in addition to the rates at which they were being used in the cycle. It is known that PI4P and PI45P2 
do not alter dramatically upon stimulation from their homeostatic  levels2,6,16,17. We hypothesized that this might 
be due to the presence of PL binding proteins that would sequester membrane phospholipids through protein-
lipid interactions, which have been shown to be important for numerous cell  functions18.
We first focused on PI45P2-binding proteins and added these to our model with reversible binding reactions 
with PL to control its use by PLCβ (Iteration 3, Fig. 2C, Supplementary Figs. 1–2 online). We performed a series 
of parameter scans of the amount of binding proteins and average ON/OFF binding rates which predicted that 
to correctly simulate temporal PI45P2 changes, the number of binding proteins should be around 1.3 × 106 per 
cell. A detailed search for known PI45P2-binding proteins in the proteome  dataset5 revealed, in close agreement 
with our prediction, a value of 1.12 × 106 per cell (Supplementary Table S6 online). Similar methodologies were 
used for PA, PI4P and DAG, and led to model results matching the experimental data (Fig. 3b,c, Supplementary 
Figure S3 online).
Model predictions of the regulation of pi cycle enzymes. PI45P2 and PI4P homeostatic levels in 
human platelets are similar, at around 1.2–1.8 × 106 molecules per cell respectively, while the estimated amount of 
plasma membrane PI is around 6 × 106 molecules per cell (Supplementary Table S1 online). This suggests unbal-
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anced phosphorylation/dephosphorylation reactions between PI and PI4P and balanced reactions between PI4P 
and PI45P2 in inactivate cells. The addition of PI4P, its binding proteins and its metabolizing enzymes PI4K, 
Figure 1.  Graphical summary of the different modelling steps. (a) The core model was produced using 
proteomics and signaling data (obtained with a single GPCR ligand, Thrombin) obtained for human platelets 
and used to generate predictions regarding PI cycle driven cell signaling. (b) Mouse platelet and nucleated cell 
proteomic data (Cell type B) were used to populate our Core Model, generate output predictions and analyse the 
impact of using data from different origins in a single model.
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Figure 2.  Schematic illustration of the PI cycle in mammalian cells and model iterations. (a) Schematic 
of the GPCR ligands and reactions in platelets covered by our model (blue). PI3K-dependent (green) and 
Gα13-dependent (grey) reactions were not included in the core model. PI Phosphatidylinositol, Ins Inositol, 
PIP3 Phosphatidylinositol-3,4,5-trisphosphate, PI45P2 Phosphatidylinositol-4,5-bisphosphate, PI34P2 
Phosphatidylinositol-3,4-bisphosphate, PI4P Phosphatidylinositol-4-phosphate, IP3 Inositol trisphosphate, 
DAG Diacylglycerol, PA Phosphatidic Acid. (b) Early iterations used a simplified Core Model to estimate the 
phospholipids synthesis rates in inactivated cells (+ PLC) and activated cells (+ PLCa). Rate labels are indicated 
as either basal rates (k) or activated rates (k’). (c) The completed Core Model schematic including lipid binding 
proteins. k14 = PIP5K, k15 = OCRL1, k16 = PI4K, k17 = SAC1. k14 to k17 represent rates before activation, k14′ to 
k16′ represent the rates after activation. k17 remains unchanged after activation.”
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Figure 3.  Comparison of experimental results and model simulations. (a) PI and Ins experimental results 
(orange dots with SD) and simulations (blue curves) after Thrombin stimulation. Secondary signaling by other, 
secreted, GPCR ligands is taken into account and assumed to happen immediately. (b) Early model iterations 
simulations showing the stabilizing impact of lipid binding proteins (BP) on the dynamics of PI45P2, PI4P and 
PA before and after activation with Thrombin. The numbers of BP and the ON/OFF rates of their binding to 
their relevant PL were determined using parameter scans. (c) The final simulations in our completed core model 
are shown together with the experimental results. Experimental results are shown with standard deviations 
when available. (References, SD and model parametisation procedures in “Methods” and Supplementary 
Tables S1-S5). Experimental data: n = 10, SEM are shown. Activation is indicated by arrow.
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OCRL1 and SAC1, could only achieve the correct dynamics of PI4P, PI45P2 and PI observed both before and 
after activation when the rates of the PI4K and OCRL1 were regulated in a manner similar to PIP5K i.e. all 
three enzymes have similar low kinetic levels before activation, which are increased upon GPCR activation. In 
contrast, the SAC1 kinetic rate constant needed to remain unchanged after GPCR activation to recapitulate the 
correct experimentally observed PL dynamics i.e. a short and synchronised burst for PI4P and PI45P2 within 
the first 20 s of the activation, followed by a return to their initial levels while PI level fall substantially to half its 
initial level within seconds and is not replenished significantly for the next 30 min (Fig. 3a,c).
In conclusion, our results suggest that the regulation of the PI cycle in both inactive and activate cells is 
achieved by mechanisms differentially controlling the enzymes involved. PI4K and PIP5K have been suggested 
to be scaffolded by proteins at the membrane, exchanging PL almost  directly19. Our simulations suggest that 
OCRL1 is also part of this complex or co-localises in the plasma membrane, being then regulated in concert 
with the kinases. SAC1, however, is regulated differently than the other PI cycle enzymes which leads to the 
hypothesis that it may not co-localize with them.
The final step of our model development (Iteration 4, see Supplementary Information for details and Sup-
plementary Figure S2D online) was to reintroduce PLCβ products, IP3 and DAG, as intermediates for Ins and 
PA. While DAG and PA levels, regulated by two simple reactions and their respective binding proteins could 
be easily modeled, cytosolic IP3 and Ins levels could not be correctly simulated by a single direct reaction. We 
were only able to match their respective dynamics by adding an intermediate step which removes IP3 rapidly, 
reflecting the production of IP4 by the kinase IP3Kb and IP2 by the PL phosphatase  INPP520. This is followed by 
slower production of Ins by a complex set of reversible  reactions21 which we simplified in our model and wrote 
as a single reaction (Fig. 2a,c, Supplementary Figure S2D online).
Gαq‑coupled receptor number governs the strength of IP3 production. We chose to model the 
PI cycle because of its central role in signalling cascades triggered by a variety of GPCR agonists. One issue with 
this approach is that the strength of the signalling is highly variable depending on the type of receptor involved, 
with some researchers arguing that differences in molecular identity, biological activation processes and post-
activation recycling of the receptors are responsible for this variability. Kinetic studies, however, demonstrate 
that GPCR signalling is primarily and rapidly down-regulated at the level of the receptors by phosphorylation, 
and by inactivation of their direct partners, the G proteins, and the RGS and PLCβ  proteins22,23. Together the 
evidence suggests that the strength of the GPCR signalling is actually a function of receptor  abundance1,24.
The experimental data we used to inform our model kinetic rate constants were obtained after Thrombin 
activation of the platelets. However, the experimental methodologies used by the different authors suggest that 
secondary GPCR signalling through secreted ADP and TxA2 release was also  activated6–11,16. We originally 
designed our Core Model to account for the activation of all their respective Gαq-coupled receptors, namely 
PAR1/4 for Thrombin, P2Y1 for ADP and TPα for Thromboxane (Fig. 4a,b, RGq = 5,000, Supplementary Table S7 
online). By solely reducing the receptor numbers to simulate only ADP activation via the P2Y1 receptor (Fig. 4b, 
RGq = 150), we were able to simulate the experimentally observed IP3 output supporting the claim that, in the 
case of Gα-coupled receptors, the strength of the signalling is indeed related to the number of receptors being 
 activated25 (Fig. 4b, Supplementary Table S7 online).
We could not find data regarding IP3 levels after TxA2 activation, however, IP3 triggers calcium cellular 
mobilization and both experimental and mathematical models have shown a relationship between cytosolic IP3 
and calcium  levels17,26. Quantification of calcium in platelets shows that TxA2-mediated activation leads to half 
of calcium being mobilized compared to Thrombin. ADP activation only triggers a fraction of IP3 and calcium 
release compared to Thrombin and  TxA227,28 (Fig. 4c). Interestingly, the number of TPα and P2Y1 receptors 
which would be involved in a TxA2 primary activation followed by the secreted ADP secondary activation is just 
under half the number of the full Gαq-coupled receptor complement (Supplementary Table S7 online). When 
modeling the likely IP3 output following the activation of TPα and P2Y1 receptors, we obtained a predicted peak 
value for IP3 roughly half that obtained with Thrombin (Fig. 4b, RGq = 1,650). This supports the hypothesis that 
IP3 levels regulate the intensity of calcium release in a GPCR receptor number dependent manner.
Applying the core model to other cell types. Given the universality of GPCR signaling and the PI 
cycle in mammalian cells we assume that the network structure and kinetic rate constants do not vary greatly 
between platelets and other cell types. Temporal expression profiles of PI45P2 and IP3 in human Purkinje cells, 
mouse N1E-115 neuroblastoma neural cells or chicken B cells DT-40 have been published and the similarities 
between them and human platelets suggest those profiles are common features in vertebrate  cells22,17,29. We thus 
hypothesised that we should be able to simulate the PI cycle and IP3 production in other cells and obtain similar 
output dynamic patterns by using cell specific protein initial concentration values, whilst leaving our model 
structure and kinetic rates unchanged (Fig. 1b).
Application to the mouse platelet using proteome data. Before proceeding to consider how appli-
cable our model was in nucleated cells, we first used data from the mouse platelet proteome, to check the model 
 behavior12. We corrected for the difference in size of the reaction compartments (25% of those in human plate-
lets, Supplementary Table S7 online) but left the ODEs untouched. Despite the protein concentrations being 
sometimes very different from their human counterparts, the simulations show almost identical temporal 
behaviors of the different PL and IP as for human platelets and levels in line with the initial PL abundancy (Sup-
plementary Figure S4 online).
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Application to nucleated cells using cell‑specific data. To demonstrate the wider utility of our model 
we next created a generic simulated nucleated cell, using an average volume of 2000 fl and calculated the size of 
the reaction compartments as described earlier. PL, IP and lipid-binding protein numbers were adapted from the 
human platelet data (Supplementary Table S7 online). We first simulated the behavior of an enlarged platelet by 
populated our nucleated PI cycle model with the protein copy numbers of a human platelet scaled to match the 
new reaction volumes (labelled pltx17). Next, protein copy numbers from the epithelial adenocarcinoma HeLa 
human cell line proteome dataset were used to populate the same  model13. In order to compare the results and in 
the absence of common data regarding GPCRs, the activation in these simulations were performed using 85,000 
molecules of GPCRs, i.e. corresponding to the same concentration of receptors for a normal human platelet. 
Given that HeLa cell protein numbers are drastically different from the enlarged platelet simulation, we expected 
a radically different series of outputs. HeLa cell simulations did indeed show some differences in the peak con-
centrations of the PLs and IPs we surveyed compared to the large platelet simulation, but overall the temporal 
dynamics were similar (Fig. 5), suggesting our model solutions are robust to changes in protein concentration 
and exhibit the correct PLCβ-dependent IP3 signaling response.
The effect of using mosaic proteomic datasets for informing model parameters. After demon-
strating the portability of our PI cycle pathway model to other cell types and its robustness when parameterised 
with cell specific protein numbers, we wanted to investigate its response when informed by a mosaic data-
set. Using our nucleated cell model, we used a proteomic dataset from the bone osteosarcoma epithelial U2OS 
human cell lines with only partial data regarding the PI cycle enzymes and missing the concentration of Gαq, IP3 
processing enzymes (IP3Kb and INPP5), OCRL1, PI4K and cPLA2  proteins30 (Supplementary Table S7 online). 
HeLa protein concentrations were used to inform the missing values. The resulting simulations led to PI, Ins and 
PA concentration profiles similar to the Hela simulations although the concentration of PI45P2, PI4P and IP3 
were much lower than expected for a cell of this size. IP3 production is significantly affected and unlikely to lead 
Figure 4.  IP3 simulations with differential receptor numbers. (a) IP3 experimental results (orange dots with 
SD) and simulations (blue curves) after Thrombin activation. (b) simulations of the impact of Gαq-coupled 
receptor numbers (RGq) on IP3 production. RGq numbers reflect primary and secondary GPCR ligand 
activation (Thrombin followed by TxA2 and ADP: RGq = 5,000; TxA2 followed by secreted ADP: RGq = 1,650; 
ADP alone: RG1 = 150). Activations occur at 100 s. (c) comparison of known IP3 and calcium mobilization 
results in platelets. in absence of experimental data on IP3 production after TxA2 activation, we are using 
known cytosolic calcium concentrations as a  proxy27. The simulations of IP3 release from a receptor number 
corresponding to a TxA2/ADP activation (RGq = 1,650) show an intermediate response as is also seen for 
calcium mobilization experimental data.
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to a realistic outcome (Fig. 6). We then utilised a series of parameters scans, to inform those protein concentra-
tions for which values were not available. Whilst we were able to find protein copy numbers which meant Core 
Figure 5.  Application to other cell types. GPCR-PLCβ outputs simulations using Hela proteome dataset (blue 
line) and compared to a hypothetical large platelet (pltx17, orange line). Reactions and kinetic parameters are 
unchanged from the original core model; reaction volumes, initial PL numbers and their binding proteins were 
adapted as described in “Methods” and Supplementary Table S7 online. Simulations are run for 5,000 s with 
activation occurring at 1,000 s (arrows).
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Model simulations could replicate the previously modelled HeLa cell behaviour, the use of partial data from a 
different cell type would not necessarily provide the correct outputs (Fig. 6, Supplementary Table S7 online).
We then considered random combinations of all the protein concentrations from the U2OS and HeLa datasets. 
The simulations showed no consistency for any PL or IP we surveyed, with 75% leading to incorrect behaviours 
(Fig. 7). Whilst 25% of the results produced the correct behaviour for IP3, these simulations did not always lead 
to correct outputs for the other PLs we surveyed such as PI4P or PA. Ultimately this suggests that combina-
tions of protein concentration values may lead to incorrect model approximations of the underlying protein 
concentrations.
Together these results suggest that combining data from different cell types does not necessarily lead to results 
that are consistent in simulating PI cycle dynamics. Indeed, it is highly likely that in the majority of cases, model 
simulations are unlikely to agree with experimentally observed results for specific cell types. To further test this 
result we undertook a sensitivity analysis to determine the influence of initial protein levels on the production of 
IP3. This revealed both commonalities and specific patterns for each cell type (Supplementary Figure S5 online). 
Specifically, similar changes in the concentration of PLCβ, PIP5K and OCRL1 lead to distinctive IP3 outputs in 
the different simulated cells.
Thus, we conclude that although our model can be populated with protein concentrations sourced from dif-
ferent cell types, to describe functional outputs, it can lead to erroneous conclusions.
Discussion
Conventionally, mathematical models of cell signalling pathways have been informed by data taken from a 
range of cell types. This is often a result of data not being available for a specific cell type to inform all kinetic 
rate constants and concentrations. Whilst to the seasoned mathematical modeller this might seem intuitive, we 
demonstrate here that the consequences should not be ignored. Here we developed a biological model of the PI 
cycle entirely based on a single quantitative proteome and multiple sets of experimental data generated under 
the same conditions for a single cell type, the human platelet. This allowed us to focus on determining in situ 
kinetic rate parameters of the reactions governed by Gαq-coupled receptors. In addition, and in contrast to most 
other published cell signalling models, we have considered how the system behaviour varies from an inactive to 
active state. This has allowed us to reveal a number of mechanisms involved in the maintenance of the observed 
steady-state before activation.
Previous mathematical models have largely ignored the cyclic generation of PI, assuming instead that it was 
available at all  times1–3 or suggested the presence of an “open” PI cycle where some PLs produced externally can 
recapitulate both steady-state and activated experimental  results31. We postulated that signalling events lead to 
the depletion of PI on the plasma membrane and termination of the signalling, while leaving a pool of PI on 
ER and Golgi membranes. Using our model, we were able to show that while there is a constant exchange of PI 
between the different membranes, the rate of plasma membrane PI replenishment does not seem to be modified 
by activation events. This leads to the conclusion that PI distribution on the different cell membranes, and the rate 
at which it can be replenished at the plasma membrane, is a major way of regulating the duration of cell signalling.
While it has been suggested that sequestering of membrane lipids by binding proteins is an integral part of cell 
homeostasis and  activation18,31,32, the involvement of PL-binding proteins in cell signalling regulation is, however, 
usually considered only after cell stimulation. We demonstrated that PL-binding proteins also play a stabilising 
role prior to signalling events, functioning as cellular sinks and limiting the availability of lipids to modifying 
enzymes such as PLC and PI3K; effectively inhibiting signalling processes. After signalling is triggered, PL-
binding proteins also regulate the maximum amount of available PL for reactions leading to intermediates such 
as IP3 and DAG. Simulations of PI45P2-binding proteins correspond to the peak quantity of PI45P2 monitored 
experimentally and we predict that this is likely to be true for all other PL-binding proteins.
Next, our model, formulated using thrombin-stimulated platelet data, was able to recapitulate known IP3 
outputs for other GPCR ligands by simply replacing the receptor numbers for each ligand with their respective 
known values. These results support the still-debated hypothesis that the number of GPCRs, rather than their 
molecular identity, regulates the intensity of this type of  signalling1,24.
We also used our model to produce a series of predictions regarding the regulation of the major enzymes 
involved in the central PI45P2 -PI4P -PI axis of the PI cycle. We predicted that three out of the four enzymes, 
namely PI4K, PIP5K and OCRL1 have their activities up- and down-regulated in concert. The co-location of 
PI4K and PIP5K has already been shown to occur  experimentally19 and the use of a protein complex contain-
ing PIP5K and PI4K shown to successfully replicate experimental observation in mathematical  modelling3. We 
now suggest adding OCRL1 to this complex. In contrast, to explain the differential abundancy of PI and PI4P/
PI45P2 as well as the distinct response of the phosphatase SAC1 to the activation signal, we predict this enzyme 
to be isolated from its counterparts. SAC1 has been shown to be restricted to discrete regions of contact between 
the plasma and ER  membranes33. Interestingly, CDPIT, otherwise known as PI-synthase, is also shows a lack 
of up-regulation after  signalling34 and is known to be located at cell membrane contact points between the ER 
and plasma membranes. It is likely that the PI4K-PIP5K-OCRL1 complex is recruited by either the receptors 
or some of their downstream effectors. There is no physical connection between the location of the complex 
and the membrane contact regions containing the different enzymes regulating the regeneration of PI and its 
location on the different membranes.
Due to the lack of detailed protein concentration and reaction rate constant values for individual cell types, 
the use of data obtained from multiple cell types is common in cell signalling models. Kinetic rates are often 
sourced from experiments performed with purified enzymes or adapted from previous modelling attempts. 
While mathematical models informed using ‘mosaic data’ have been crucial in understanding mechanisms that 
underlie processes within cells, combining data from different mathematical models of the same pathway are 
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Figure 6.  Simulations with mosaic proteome datasets. GPCR-PLCβ outputs simulations comparing HeLa 
(dashed line) and 2 U2OS datasets (“scanned” or “mosaic”). Because the values for PI4K, OCRL1, Gαq, cPLA2 
and IP3 modifying enzymes are missing from the U2OS proteome, we performed a series of scans to estimate 
the missing protein numbers (“scanned”, see Supplementary Table S7 for details) that allow results similar to 
those obtained with the HeLa dataset (“HeLa”) and compared them to a mosaic dataset created by using HeLa 
protein numbers to replace the missing U2OS numbers (“mosaic”). The results show that the mosaic dataset 
generates outputs for PI45P2 (PIP2), PI4P and IP3 are unlikely to lead to a cell signaling response. Simulations 
are run for 5,000 s with activation occurring at 1,000 s (arrows).
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Figure 7.  Simulation results of systematic “mix-and-match” of protein numbers between HeLa and U2OS 
cells proteomic data. The copy numbers of the 12 key proteins surveyed in our model (Gαq, smG, PLCβ, the 
combined IP3 modifying enzymes, DGK, LPP, CDIPT, OCRL1, PI4K, PIP5K, SAC1 and cPLA2) were taken 
from either the HeLa or U2OS proteome (12, 34), or from the calculated numbers for U2OS missing data 
shown in supplementary Table S7, and systematically mixed using Parameter Scans in COPASI 15. 75% of the 
4,096 simulations obtained lead to incorrect dynamic behaviours for the outputs monitored with our model. 
Simulations are run for 5,000 s with activation occurring at 1,000 s (arrows), #molecules per cell, s seconds.
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often difficult. This is because model formulations often differ, meaning parameter dimensions do as well. This 
is further compounded by the fact that data is not always available to inform all model parameters, meaning 
uninformed cell specific parameters are often determined using similar processes in other cell types or are sim-
ply estimated. We hypothesised that fully informing a mathematical model of a pathway using cell type-specific 
data would lead to more accurate predictions of the pathway dynamics. We demonstrated that our PI model 
of a human platelet demonstrated similar behaviour when informed by mouse platelet data, where the kinet-
ics were assumed the same, but protein concentrations varied. In extending the model to that applicable to a 
nucleated HeLa mammalian cell, similar observations were made. However, maintaining the same kinetic rate 
constant values but using protein concentrations obtained from two different cell types led to widely varying 
dynamical predictions for PL and IP3. Our sensitivity analysis of the impact of protein levels on the production 
of IP3 suggested that each cell has a specific balance of PL/IP modifying enzymes working together to lead to the 
correct behaviour. With only a small number of proteomic datasets available at this time, we have been unable 
to identify how this balance is established. We believe that further information from other nucleated cells will 
be needed to understand it.
The long-term goal of biological modelling is to recapitulate processes that govern cell behaviour. Our expe-
rience in modelling the PI cycle was that there was too much variability in kinetic reaction rate constants and 
protein concentration published from prior partial models to build a comprehensive model of the pathway. In 
order for parameterisation of mathematical models for specific cell-types to be more consistent, the collection 
of comprehensive experimental data informing the concentration of cellular components and their dynamic 
behaviour needs to occur. Currently, such values are generally informed by traditional methodologies such as 
western blotting or lipid chromatography, both of which are limited in the number of molecules they can simulta-
neously characterise. They also suffer from a lack of uniformity and reproducibility. Omics technologies are now 
available to process high numbers of molecules using highly standardised protocols, which should allow for such 
issues to be  overcome35. Extensive quantitative proteomic, metabolomic and lipidomic datasets for commonly 
available cell lines already provide a valuable resource for modellers. Given the number of signalling pathways 
in eukaryotic cells that are being considered for mathematical modelling, the rapid expansion of cell-specific 
omics generated data sets, are likely to become a central part of ensuring mathematical models of signalling 
pathways are quantitatively well informed.
Methods
Further details of the biological rationale and of the description of the different iterations of the model are avail-
able in the Supplementary Information document.
estimation of compartment sizes. Our core model consists of 3 compartments: the plasma membrane, 
the cytosol and the organelles. The volume occupied by the platelet plasma membrane, including the open can-
icular system (OCS) inside the cytoplasm, was calculated to be around 1 fl. Based on published observations, 
the size of the cytoplasm was reduced as the observed volume of platelets is filled by organelles such as vesicles, 
ER remnant, mitochondria and the OCS estimated to occupy up to 40% of the internal volume. Most of the 
remaining volume contains cytoskeletal proteins and glycogen granules and is calculated to occupy around 1 
to 2 fl37,41,42. We estimated the mouse platelet plasma membrane and cytosol volumes to be around 0.25 fl each 
while the nucleated cells average plasma membrane and reaction cytosol volumes at around 17 fl each based on 
a 2000 fl overall cell volume.
initial parameters. Our model takes into account the concentration of protein and lipids relevant for 
each reaction. Data for protein copy numbers were obtained from a human platelet  proteome5 (Supplementary 
Table S2 online) while initial and post-activation time-resolved data for the Phospholipids (PL) and Inositol 
Phosphates (IP) were collated from several  publications6–10,14,16,25,43–48 (Fig. 3, Supplementary Table S1 and Sup-
plementary Figure S1 online). For collated pools of proteins, the UniProt database was first mined using the PL 
names, followed by a search of the quantitative proteome using the UniProt codes (Supplementary Table S2, S6 
and S7 online). Although their binding affinities for the different PL are likely to be variable, we parametised the 
different on/off rates on the assumption of average kinetics.
estimating kinetic rate constants. We used the free software COPASI (v4)15 to build our model starting 
from a reduced basic network of reactions. All molecules were considered as “well-mixed” inside each compart-
ment. Mass Action kinetics were assumed in modelling the respective reactions. The governing equations were 
solved using the deterministic method (LSODA) solver. Reaction enzymes were not written as modifiers as their 
concentrations were important for our model. Activation by ligands were written as events after the start of the 
simulation. All enzymatic activations were terminated by either the production of an inactive protein (inactiva-
tion) or by the return to the initial basal activity state (reset). For each reaction the default rate was first selected 
then a series of parameter scans were performed, starting at ± 4 orders of magnitude until the values were pro-
ducing time-resolved curves for each and every PL and IP output in the model matching the experimental data 
using a fit-by-eye. Steady-state analysis and Time Series Sensitivity Analysis were performed on all reactions that 
occur before the activation event, and the protein and PL/IP concentrations adapted accordingly. Parameters 
sets that led to a deviation of more than 20% from the experimental data were rejected and the full analysis 
restarted. Schematic diagrams of the reactions and the parameters are shown in Table S3. The computed initial 
molecule numbers are listed in Table S4. IP3 Time Series Sensitivity Analysis were performed using the in-built 
“Sensitivities” function in  COPASI15, looking at the scaled variation of IP3 with respect to the variation of the 
protein initial concentrations, with the delta factor set at 0.2.
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Data availability
The model was deposited in the BioModel  database49 under the accession number MODEL2006300001.
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